ReviewNature reviews. Microbiology2009
Clostridium difficile infection: new developments in epidemiology and pathogenesis.
Review in Nature reviews. Microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07261826 (Real-World Study on Fecal Microbiota Transplantation), which is not on this map. Cited by 726 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics
Who cites it
726 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2020Pooled it
- Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence ofBMJ open · 2023Trial
- Genomic evolution and re-emergence of a multidrug-resistantEmerging microbes & infections · 2026Article
- Comparative evaluation of three high-molecular-weight DNA extraction kits for Oxford Nanopore sequencing ofMicrobiology spectrum · 2026Article
- Development a novel in silico mRNA vaccine against Clostridium difficile.Journal, genetic engineering & biotechnology · 2026Article
- Argyrin B exhibits potent therapeutic efficacy in a Clostridioides difficile-infection mouse model while preserving microbiota functionality.npj antimicrobials and resistance · 2026Article
- Design and Synthesis of Phosphonoproline-Proline Bioisosteric Mimetics of Proline Dimers: Pseudopeptide Constructs as Potential Inhibitors of the Zn-Metalloprotease PPEP‑1 Associated withACS medicinal chemistry letters · 2026Article
- Coupling Far-Western Blotting with Peptide Microarrays Reveals Novel E-Cadherin Spore-Surface Ligands inJournal of proteome research · 2026Article
- Development and Evaluation of Exosporium-Anchored Bioluminescent and Fluorescent Reporters for TrackingACS synthetic biology · 2026Article
- Wastewater reuse for production of plant-based foods: does spore-formingApplied and environmental microbiology · 2026Review
- Phylogenomic analysis of the collagen-like BclA proteins inApplied and environmental microbiology · 2026Article
- Modeling Clostridioides difficile toxin pathogenesis and antiserum protection in an immunocompetent intestine-on-chip platform.Scientific reports · 2026Article
- Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types.Biotechnology and bioengineering · 2026Article
- Pleiotropic roles of the MATE transporter CD20030 inFrontiers in microbiology · 2026Article
- Pangenome-GWAS analysis ofCanadian journal of microbiology · 2026Article
- HumanbioRxiv : the preprint server for biology · 2025Article
- Characterization of a hypersporulating strain derivativebioRxiv : the preprint server for biology · 2025Article
- Effects of bacteriophages on gut microbiome functionality.Gut microbes · 2025Review
- Article
- Article
666 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.
Indexed as
Identifiers
19528959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.